BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220906
DTEND;VALUE=DATE:20220909
DTSTAMP:20260516T032051
CREATED:20220524T085905Z
LAST-MODIFIED:20220524T085905Z
UID:34213-1662422400-1662681599@www.pharmajournalist.com
SUMMARY:Optimizing AAV Safety Summit
DESCRIPTION:Hundreds of clinical trials using AAV are underway\, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline\, the need to administer high doses\, the clinical holds placed on gene therapy trials\, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that’s fit for purpose! \nIn this setting\, the inaugural Optimizing AAV Safety Summit is bringing together key leaders focussed specifically on solving AAV safety challenges across toxicology\, pharmacology\, non-clinical study leads\, clinical development safety specialists and bioanalysis innovators to gain insights on optimizing AAV safety processes and benefit-risk analysis to shorten timelines and prevent potential delays. \nJoin us in Boston alongside key biotech and pharma leaders from the likes of Spark Therapeutics\, Ask Bio\, Eli Lilly\, Takeda\, and more in the AAV space who are prioritizing the development of safe and effective genetic therapies\, learn how clinical safety signals have changed how companies are approaching their pipeline progression\, and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development. \nTo know more visit: https://ter.li/r92wow
URL:https://www.pharmajournalist.com/event/optimizing-aav-safety-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220906
DTEND;VALUE=DATE:20220909
DTSTAMP:20260516T032051
CREATED:20220713T080736Z
LAST-MODIFIED:20220713T080736Z
UID:34660-1662422400-1662681599@www.pharmajournalist.com
SUMMARY:5th International Cannabinoid-Derived Pharmaceuticals Summit
DESCRIPTION:Over the last half-decade\, we have witnessed game-changing developments within the cannabinoid field\, driving it into a new era of rigorous research\, promising clinical trials and multimillion-dollar deals. Right now\, there are 50 cannabinoid therapeutic trials taking place at phases 2 and 3\, pushing for approval to meet the clinical needs of patients with chronic pain\, cancer\, psychiatric conditions and much more. Despite these positive changes and rapid industry growth there remains key challenges to overcome for drug developers regarding the human evidence gap\, funding and changing regulation – to name just a few. \nThe 5th International Cannabinoid-Derived Pharmaceuticals Summit is uniting drug developers\, investors\, solution providers and academics from around the globe working to overcome these challenges and progress the field of cannabinoid therapeutics. 35+ expert speakers will lead sessions on critical topics across 3 days of presentations\, panel discussions and interactive workshops in Boston. \nAgenda highlights include: \n\nPresent a poster of your drug development pipeline at our investor networking session\, and connect with the decision makers looking to fund promising cannabinoid therapeutics\nGet the most up-to-date regulatory perspectives from the FDA and other organizations with Dominic Chiapperino (FDA) and Cassie Taylor\n(FDA)\nProduce and source high-purity cannabinoids from synthetic\, plant-based and biosynthetic sources with Purisys\, Kinetochem and our other world-leading partners\nHear from the key opinion leaders at the forefront of next-generation cannabinoid-derived pharmaceutical development including Alistair Vickery (Emyria)\, Brian Murphy (Former CEO of Emerald Bioscience) and Jeff Chen (Radicle Sciences)\nStreamline successful late-stage clinical trials and be the next one across the finish line with a multi-format and highly interactive session with Sud Agarwal (Cannvalate)\nJoin 2 half-day workshops – one dedicated to bridging the gap between OTC and prescribed pharmaceuticals\, and an additional behind-the-scenes workshop on the psychedelics field\, preparing you for exploration into a new area\nConnect with 80+ thought leaders and industry peers as they come together to drive discussion and progress across the 3-day event\n\nThe Summit focuses on the real science in the cannabinoid industry and is the only chance to connect with likeminded\, analytical professionals looking to move the dial forward in this exciting space. Check out the event guide for the full agenda
URL:https://www.pharmajournalist.com/event/5th-international-cannabinoid-derived-pharmaceuticals-summit/
LOCATION:Boston\, MA (venue TBC)
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR